| 0.7252 -0.011 (-1.51%) | 09-15 13:31 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.46 | 1-year : | 1.88 |
| Resists | First : | 1.25 | Second : | 1.61 |
| Pivot price | 0.73 |
|||
| Supports | First : | 0.68 | Second : | 0.57 |
| MAs | MA(5) : | 0.71 |
MA(20) : | 0.75 |
| MA(100) : | 1.73 |
MA(250) : | 1.83 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 19.7 |
D(3) : | 15.5 |
| RSI | RSI(14): 30.6 |
|||
| 52-week | High : | 3.77 | Low : | 0.68 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ DARE ] has closed above bottom band by 39.6%. Bollinger Bands are 86.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.75 - 0.75 | 0.75 - 0.76 |
| Low: | 0.68 - 0.69 | 0.69 - 0.69 |
| Close: | 0.73 - 0.74 | 0.74 - 0.74 |
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
Mon, 14 Sep 2026
Dare Bioscience (DARE) Reports Phase 1 Trial Results for Topical Sildenafil Cream - GuruFocus
Mon, 14 Sep 2026
Sildenafil cream showed 187-fold lower peak blood levels than an oral dose - Stock Titan
Fri, 11 Sep 2026
Form 8K Dare Bioscience Inc For: 11 September By Investing.com - Investing.com Nigeria
Fri, 11 Sep 2026
Dare Bioscience amends bylaws to lower quorum for shareholder meetings - Investing.com
Fri, 11 Sep 2026
DARE: Commercial launches and late-stage clinical milestones mark a pivotal year for women's health innovation - TradingView
Fri, 11 Sep 2026
DARE: Two revenue-generating women's health products launch in 2026, with key clinical readouts ahead - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 1.295e+007 (%) |
| Held by Institutions | 12.3 (%) |
| Shares Short | 601 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.98e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 582.5 % |
| Return on Equity (ttm) | -39.3 % |
| Qtrly Rev. Growth | 1.37e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 3.29703e+006 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -18.3 |
| Dividend | 0 |
| Forward Dividend | 1.17e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|